ADVM / Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study

REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish more_horizontal

REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish more_horizontal

Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-a more_horizontal

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinica more_horizontal

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet A more_horizontal

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low dose more_horizontal

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low dose more_horizontal

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low dose more_horizontal